HIMS Sees Accelerating Growth In Q2

Another excellent report from HIMS, which has been one of our best-performing stocks this year. Revenue growth accelerated to 52% in Q2, up from 46% in Q1, as the launch of GLP-1 weight loss drugs and continued momentum in its other categories drew users to the platform. Subscribers were up an impressive 43% year-over-year. Management continues to see opportunities in expanding its existing offerings as well as adding new health verticals. HIMS is still a great growth stock, but the market has caught up to the value somewhat. It still looks attractive at current prices. I'm raising the fair value from $17 up to $21 per share.

Watch List

APPF 0.31%
S 7.90%
NTNX 29.15%
CRWD 94.58%
SEMR 10.97%
SNOW 23.53%
SE 72.46%

Buy List

TSM -26.30%
GOOG -44.13%
NYAX -44.21%
MSFT -25.64%
ASR -28.40%
HRMY -49.18%
YOU -51.94%
ADBE -31.43%

Hold List

ZETA -15.39%
ODD -23.48%
FLYW -8.26%
CELH 1.94%
TOST 25.67%
CPNG 5.62%
HIMS 76.00%
PAYC -23.36%
MNDY 30.15%
GLBE -2.02%
ZS 25.67%
V -3.45%
ADSK 6.74%
NOW 13.33%
ABNB -17.94%
MELI -22.12%
FTNT 7.86%
TEAM 25.43%